LSR Stock Price and Chart — GETTEX:LSR

Name: LSR price data
Creator: GETTEX

Compare with CEL-SCI Corporation

Profile

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Financials

Performance

Revenue to profit conversion

Debt level and coverage

Earnings

Next:—

Ideas

This Stock Has the Potencial to Double Here I present to you exclusively an undervalued share that few analysts have on their radar. The Cel-Sci share has recovered significantly from its lows reached in 2023 and formed a wave 1. There has been a correction, so we can expect big upward waves 3 and 5 soon. From an option sentiment perspec

by Ochlokrat

CVM Stock Target $5.27 swing trade High risk trade to upside but I like it Trend line tested

by brian.michael.399

CVM 1Y RSI is trending down. MFI is trending down. -Both have reached a top. 5Y RSI is trending up. MFI is trending up. -Both have bottomed. ALL RSI is reaching a bottom. MFI is trending down. There is a gap around $0.80 and $1. Prediction: I think we will continue falling near the $0.80 and $1 rang

by Kyo026

CVM; Trend Analysis with ASCO review Disclaimer I am very invested in CVM, for a multitude of reasons, first as a scientist, second as an investor, third as my ego. I believe their recent clinical trial results are phenomenal, and illustrate it's potential as the pre-treatment for cancer in immuno-competent patients with appropriate

by DoctorFaustus

CVM Bullish Price tested 4 fibonacci levels to close just under the .78 level. In addition the MACD just crossed on the daily. Looks like $12.21 may act as resistance, in which case we may see a retracement to the $11.80-$11.22 level. Target: $13.01 short term. $14.26-$16.71 possible if it starts to squeez.

by Master_of_Fine_Charts

CVM and Multikine; Rating and Confidence Reaffirmed Disclaimer I am long $CVM to the tune of X0,000 shares (and growing). I genuinely believe, as a scientist, biochemist, and analyst, in Cel-Sci Corporation's Multikine. This article serves as the thesis that $CVM deserves that I have given to other stocks. As always buy shares, options are dangerous

by DoctorFaustus

Nice Long for CVM **SMALL ACCOUNT FRIENDLY PLAY** Peep this insane chart! **CVM** Long above $12.50 Short below $11.22 $SPY $CVM

by Smoothjb83

CVM; Breakout from bear pennant, prime for liftoff Disclaimer General disclaimer here. Short but sweet, we have sustained breakout from the bear pennant, we have a dwindling short pool (460k as of today borrowable from Fidelity, down from ~600k on Monday). Less kick in the shorts, and they have until the 20th of this month to sustain the price c

by DoctorFaustus

CVM; Possible break of pennant into Gamma Squeeze Disclaimer Not financial advice, blah blah blah. Looking towards the end of current pennant into a gamma squeeze... Options for 8/20 look like a massive gamma at 10 possible, with another big jump at 12.5 and 15. We could see a massive impulse up with intense gamma pressure from ~1.2 million shar

by DoctorFaustus

CVM; An Open Letter for a Large Investor This is an open letter to all large institutional investors with significant biotechnology/pharmaceutical experience. The Company Cel Sci Corp is a small, Immunology based biotech with a small pipeline outside of Multikine. 41 million shares outstanding with only State Street, BlackRock and Vangu

by DoctorFaustus

See all ideas

Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange CEL-SCI Corporation stocks are traded under the ticker LSR.

Yes, you can track CEL-SCI Corporation financials in yearly and quarterly reports right on TradingView.

CEL-SCI Corporation is going to release the next earnings report on Aug 17, 2026. Keep track of upcoming events with our Earnings Calendar.

LSR net income for the last quarter is ‪−4.73 M‬ EUR, while the quarter before that showed ‪−4.66 M‬ EUR of net income which accounts for 0.00% change. Track more CEL-SCI Corporation financial stats to get the full picture.

No, LSR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.

Like other stocks, LSR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CEL-SCI Corporation stock right from TradingView charts — choose your broker and connect to your account.

CEL-SCI Corporation

Compare with CEL-SCI Corporation

Key stats

Upcoming earnings

Profile

Financials

News

Ideas

Frequently asked questions

CEL-SCI Corporation

Compare with CEL-SCI Corporation

Key stats﻿

Upcoming earnings﻿

Profile

Financials﻿

News﻿

Ideas﻿

Frequently asked questions

Key stats

Upcoming earnings

Financials

News

Ideas